Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey W Scott

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancer Chemotherapy and Pharmacology|September 30, 2016
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumorsJohn Sarantopoulos, Sanjay Goel, Vincent Chung, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 22, 2017
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)Byoung Chul Cho, Dong-Wan Kim, Alessandra Bearz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 22, 2019
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B StudyEnriqueta Felip, Filippo G de Braud, Michela Maur, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancer Chemotherapy and Pharmacology|September 30, 2016
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumorsJohn Sarantopoulos, Sanjay Goel, Vincent Chung, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 22, 2017
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)Byoung Chul Cho, Dong-Wan Kim, Alessandra Bearz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 22, 2019
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B StudyEnriqueta Felip, Filippo G de Braud, Michela Maur, et al.
Pageof 2